Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved ...
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its ...
Nurtec ODT (rimegepant) is a brand-name drug prescribed for treating and preventing migraine in adults. Nurtec ODT comes as a tablet that dissolves in your mouth. The dosage can vary depending on ...
The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...
Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine ...
Migraines can be debilitating. For those who have them, these severe headaches can get in the way of everyday life activities ...
The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...
Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...
The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...
Sales of Nurtec ODT (rimegepant) – approved as an oral therapy for migraine prevention and acute treatment – reached $194 million in sales in the fourth quarter of 2022. It competes with other ...